Journal · Updated 2026-08-11
Delaware Medicaid and GLP-1s in 2026: The Quietly Stable Covering State
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Delaware covers GLP-1 medications for weight loss under Medicaid — Wegovy, Zepbound, and Saxenda, with prior authorization — and appears on every 2026 covering-state count: KFF's January thirteen, the April tracker verification, the July count of roughly eleven. What makes Delaware notable on this site is what is absent from its record: no 2026 restriction, no pending prohibition bill in our source review, no reported budget fight over the benefit. In a year when California, Pennsylvania, New Hampshire, and South Carolina cut coverage outright and Michigan and Virginia tightened to near-surgical criteria, a clean covering row is the rarest status in the dataset — and worth exactly one caveat: stability on a tracker is a snapshot, not a warranty.
What the record shows, and what it doesn't
The trackers verify the three-drug list and the PA requirement; our source review found no published Delaware-specific BMI threshold, step-therapy schedule, or renewal rule of the kind Michigan and Virginia print. That absence cuts two ways. It may mean Delaware runs the standard covering-state PA package — documented BMI at the program's threshold, comorbidity records where required, lifestyle-attempt evidence, prescriber persistence, the whole PA-guide checklist — without extraordinary gates. Or it may mean the gates exist in plan documents we have not sourced. This page will not invent the missing criteria. The check that resolves it takes one call: Delaware Medicaid pharmacy services, or your managed-care plan's pharmacy line, asking which drugs are preferred for the weight-management indication and what the PA requires. If a reader sends us the current criteria document, the corrections desk upgrades this page from tracker-verified to primary-sourced — that exchange is the entire model.
The doors, the floor, and the annual habit
Everything structural holds in Delaware as everywhere: the diabetes door is federally required; the cardiovascular, sleep-apnea, kidney, and MASH doors generally must be covered with PA under federal rules, per the indication-door playbook; the under-21 EPSDT path continues; and the cash floor — compounded semaglutide near one hundred dollars a month, tirzepatide under one hundred seventy on current promotional cards, with the verification homework attached — is the fallback nobody covered needs and everybody denied should price. The one Delaware-specific habit worth adopting: because every neighboring trend line points toward restriction, put the coverage re-check on an annual calendar even here. The change ledger is where any Delaware move would land, dated and sourced, and the Medicaid hub holds the national picture.
Questions people ask
Does Delaware Medicaid cover Wegovy or Zepbound for weight loss in 2026?
Yes — Wegovy, Zepbound, and Saxenda are covered with prior authorization, and Delaware appears on every major 2026 covering-state count with no recorded restriction or pending cut in our source review. Confirm your specific managed-care plan's PA requirements before prescribing.
What does Delaware's prior authorization require?
The trackers verify that PA is required but our review found no published Delaware-specific criteria document of the Michigan or Virginia kind. Expect the standard covering-state package — BMI documentation, comorbidities where applicable, lifestyle-attempt evidence — and get the actual current criteria from Delaware Medicaid pharmacy services or your plan before submitting. We won't invent thresholds we can't source.
Is Delaware's coverage at risk?
Nothing in our sources shows a pending Delaware restriction — which is itself unusual in 2026. Treat stability as a snapshot: the states that cut coverage this year mostly did it through annual budget bills, so an annual re-check is the rational habit even in the calmest covering state.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.